keyword
MENU ▼
Read by QxMD icon Read
search

rheumatoid arthritis remission

keyword
https://www.readbyqxmd.com/read/28228278/immunopathogenesis-of-rheumatoid-arthritis
#1
REVIEW
Gary S Firestein, Iain B McInnes
Rheumatoid arthritis (RA) is the most common inflammatory arthropathy. The majority of evidence, derived from genetics, tissue analyses, models, and clinical studies, points to an immune-mediated etiology associated with stromal tissue dysregulation that together propogate chronic inflammation and articular destruction. A pre-RA phase lasting months to years may be characterized by the presence of circulating autoantibodies, increasing concentration and range of inflammatory cytokines and chemokines, and altered metabolism...
February 21, 2017: Immunity
https://www.readbyqxmd.com/read/28217975/clinical-trials-aiming-to-prevent-rheumatoid-arthritis-cannot-detect-prevention-without-adequate-risk-stratification-the-prompt-trial-as-example
#2
Leonie E Burgers, Cornelia F Allaart, Tom Wj Huizinga, Annette Hm van der Helm-van Mil
Objective Prevention of Rheumatoid Arthritis (RA) was the aim of several trials in undifferentiated arthritis (UA), with overall negative results. As preparatory work has revealed that only ∼30% of UA-patients progress to RA, we hypothesized that inclusion of patients without imminent RA could lead to false-negative results. We aimed to evaluate this hypothesis by re-investigating the PROMPT-trial (one-year course of methotrexate (MTX) versus placebo in UA) after exclusion of patients without a high-risk on RA-development...
February 19, 2017: Arthritis & Rheumatology
https://www.readbyqxmd.com/read/28214924/characteristics-and-outcomes-of-rheumatoid-arthritis-patients-who-started-biosimilar-infliximab
#3
Yoon-Kyoung Sung, Soo-Kyung Cho, Dam Kim, Soyoung Won, Chan-Bum Choi, So-Young Bang, Seung-Jae Hong, Hyoun Ah Kim, Eun-Mi Koh, Hye-Soon Lee, Chang-Hee Suh, Dae-Hyun Yoo, Sang-Cheol Bae
To compare the characteristics of rheumatoid arthritis (RA) patients receiving either biosimilar or originator infliximab and to identify the effectiveness and safety of biosimilar infliximab in RA patients in real-world practice. RA patients who started either biosimilar or originator infliximab were selected using the prospective biologic disease-modifying anti-rheumatic drugs (DMARDs) registry: BIOlogics Pharmacoepidemiologic StudY (BIOPSY). Baseline characteristics of the two groups were compared, and short-term treatment outcomes, including DAS28-ESR and HAQ-DI scores, were compared after initiation of biosimilar or originator infliximab...
February 18, 2017: Rheumatology International
https://www.readbyqxmd.com/read/28214674/development-of-a-quick-serum-il-6-measuring-system-in-rheumatoid-arthritis
#4
Kensuke Koyama, Tetsuro Ohba, Kentaro Ishii, Giman Jung, Hirotaka Haro, Kenichi Matsuda
OBJECTIVE: Interleukin-6 (IL-6) plays a crucial role in the pathogenesis of rheumatoid arthritis (RA). Both fulfillment of remission criteria and assessment of other methods of evaluation of RA are important for preventing joint damage progression. Measurement of serum IL-6 concentrations has been reported to be useful for monitoring RA disease activity. However, it takes at least 4-5h to measure serum IL-6 concentrations using traditional methods, which limits its utility during routine assessment in daily clinical practice settings...
February 16, 2017: Cytokine
https://www.readbyqxmd.com/read/28213794/selected-cytokine-pathways-in-rheumatoid-arthritis
#5
REVIEW
Mélissa Noack, Pierre Miossec
Rheumatoid arthritis (RA) is a chronic inflammatory disease leading to joint destruction. Cytokines play a key role in its pathogenesis. They contribute to the induction and maintenance of inflammation and thus provide therapeutic targets. Many cytokines are involved in RA, and this review focuses on a few critical ones: tumor necrosis factor (TNF), interleukin (IL)-6, IL-1, IL-17, and GM-CSF. TNF and IL-6 are both well-established targets in RA treatment, and new biologic agents are reaching the market. IL-1 represents a more complex cytokine as results in humans do not reach those in animal models...
February 17, 2017: Seminars in Immunopathology
https://www.readbyqxmd.com/read/28205411/perceptions-of-doppler-ultrasound-for-rheumatoid-arthritis-disease-activity-assessment-and-education
#6
Fredrick Joshua, Christine Bailey, Mona Marabani, Evange Romas, Raymond White, Peter Wong
AIM: The aim of this qualitative study was to report the findings of the Defining rheumatoid arthritis progression using Doppler Ultrasound in Clinical practice (DEDUCE) Medical Practice Activity, which was developed to facilitate the utilization of Doppler ultrasound (DUS) by Australian rheumatologists in the treatment of patients with rheumatoid arthritis (RA). METHOD: Twenty-one rheumatologists recruited a total of 80 patients with RA in Disease Activity Score of 28 joints (DAS28) remission for DUS assessment and completed a pre- and post-activity questionnaire assessing their experience with DUS, as well as a 6-month follow-up questionnaire...
February 16, 2017: International Journal of Rheumatic Diseases
https://www.readbyqxmd.com/read/28205333/longitudinal-study-of-clinical-prognostic-factors-in-patients-with-early-rheumatoid-arthritis-the-predict-study
#7
Paul Bird, Dave Nicholls, Rina Barrett, Julien de Jager, Hedley Griffiths, Lynden Roberts, Kathleen Tymms, Philip McCloud, Geoffrey Littlejohn
AIM: To assess the association between baseline clinical prognostic factors and subsequent Disease Activity Score of 28 joints (DAS28) remission in early rheumatoid arthritis (RA). METHODS: Data were collected using point of care clinical software from participating rheumatology centres. Patients aged 18 years or over whose date of clinical onset of RA was within the previous 12-24 months, who had at least 6 months of follow-up data and a DAS28-ESR (erythrocyte sedimentation rate) score recorded between 12 and 24 months from first being seen for RA were included...
February 16, 2017: International Journal of Rheumatic Diseases
https://www.readbyqxmd.com/read/28196776/ebv-induced-lymphoproliferative-disorders-in-rheumatic-patients-a-systematic-review-of-the-literature
#8
Alvise Berti, Mara Felicetti, Susanna Peccatori, Roberto Bortolotti, Anna Guella, Paolo Vivaldi, Luca Morelli, Mattia Barabareschi, Giuseppe Paolazzi
OBJECTIVES: Epstein-Barr virus (EBV) is involved in the pathogenesis of approximately 40% of lymphoproliferative disorders (LPDs) arising in patients receiving immunosuppressive treatment (IST) for rheumatic diseases, but data from large cohorts are still not available. We aimed to identify clinicopathological features, management and outcome of this condition. METHODS: We reviewed all published cases of EBV-encoded RNA (EBER)-positive LPDs and included in our analysis one unpublished patient diagnosed in our Hospital...
February 11, 2017: Joint, Bone, Spine: Revue du Rhumatisme
https://www.readbyqxmd.com/read/28183330/th17-and-cd24-hi-cd27-regulatory-b-lymphocytes-are-biomarkers-of-response-to-biologics-in-rheumatoid-arthritis
#9
Sarah Salomon, Caroline Guignant, Pierre Morel, Gauthier Flahaut, Clément Brault, Clément Gourguechon, Patrice Fardellone, Jean-Pierre Marolleau, Brigitte Gubler, Vincent Goëb
BACKGROUND: The aim was to describe the regulatory B and T cells (Breg and Treg) and T helper 17 (Th17) lymphocytes before and under treatment with biologic drugs, and to assess their potential predictive value as biomarkers of response in rheumatoid arthritis (RA). METHODS: This was a non-randomised, single-centre, prospective study. Patients with active RA (American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) 2010) who required the initiation or switch to any biologic drug except rituximab were included...
February 10, 2017: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/28178142/treatment-of-rheumatoid-arthritis-with-biologics-may-exacerbate-htlv-1-associated-conditions-a-case-report
#10
Yukiko Terada, Koju Kamoi, Kyoko Ohno-Matsui, Kazunori Miyata, Chinami Yamano, Ariella Coler-Reilly, Yoshihisa Yamano
RATIONALE: There are roughly 5 to 10 million persons infected with human T-lymphotropic virus type 1 (HTLV-1) worldwide, and the safety of treating this population with biologics remains poorly understood. PATIENT CONCERNS AND DIAGNOSIS: An HTLV-1-infected 66-year-old female with HTLV-1 uveitis (HU) and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Her HU had been in remission and her HAM/TSP symptoms had been managed effectively with oral steroids for years...
February 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28176199/effects-of-antirheumatic-drug-underutilization-on-rheumatoid-arthritis-disease-activity
#11
Mohammad A Y Alqudah, Sayer Al-Azzam, Karem Alzoubi, Mohammad Alkhatatbeh, Khaldoon Alawneh, Ola Alazzeh, Bayan Ababneh
BACKGROUND: Following the recommended guidelines is crucial for achieving patient remission in rheumatoid arthritis. The aim of this study was to assess the effect of proper drug utilization of antirheumatic drugs on disease activity and drug safety in Jordan. METHODS: In a retrospective cross-sectional study, patient's demographics, clinical variables, drug regimens and side effects were recorded and the 28-joint disease activity scores were calculated. Patients were stratified into high, moderate, low disease activity or remission group...
February 8, 2017: Inflammopharmacology
https://www.readbyqxmd.com/read/28161110/-discontinuation-or-tapering-strategies-of-biologics-in-rheumatoid-arthritis-in-remission
#12
A Mallick, B Fautrel, F Sagez, C Sordet, R-M Javier, H Petit, E Chatelus, N Rahal, J-E Gottenberg, J Sibilia
The arrival of new drugs and new therapeutic strategies allowed to reach sustained remission in an increasing number of patients with rheumatoid arthritis. The study of biologic disease-modifying anti-rheumatic drugs (bDMARDs) adaptation strategies is a need to optimize the benefit/risk balance and cost/effectiveness ratio of these molecules. Current recommendations such as EULAR 2016 propose tapering bDMARDs, especially when combined with a csDMARD, when the patient is in remission after stopping persistent glucocorticoids...
February 1, 2017: La Revue de Médecine Interne
https://www.readbyqxmd.com/read/28160488/atherosclerosis-is-not-accelerated-in-rheumatoid-arthritis-of-low-activity-or-remission-regardless-of-antirheumatic-treatment-modalities
#13
Aikaterini Arida, Athanasios D Protogerou, George Konstantonis, Kalliopi Fragiadaki, George D Kitas, Petros P Sfikakis
No abstract text is available yet for this article.
February 4, 2017: Rheumatology
https://www.readbyqxmd.com/read/28160411/active-synovitis-in-the-presence-of-osteitis-predicts-residual-synovitis-in-patients-with-rheumatoid-arthritis-with-a-clinical-response-to-treatment
#14
Jun Fukae, Kazuhide Tanimura, Masato Isobe, Akemi Kitano, Mihoko Henmi, Maria Nakai, Yuko Aoki, Fumihiko Sakamoto, Akihiro Narita, Takeya Ito, Akio Mitsuzaki, Megumi Matsuhashi, Masato Shimizu, Tamotsu Kamishima, Tatsuya Atsumi, Takao Koike
AIM: To clarify the relationship between active synovitis/osteitis and subsequent residual synovitis (R-synovitis) in patients with rheumatoid arthritis (RA). METHODS: Three hundred and twenty finger joints of 16 patients with active RA at baseline (Disease Activity Score with 28 joints - erythrocyte sedimentation rate > 3.2) who subsequently achieved clinical low disease activity or remission afterwards were analyzed. Synovial vascularity (SV) was assessed according to a semi-quantitative ultrasound score (grades 0-3)...
February 3, 2017: International Journal of Rheumatic Diseases
https://www.readbyqxmd.com/read/28153828/clinical-benefit-of-1-year-certolizumab-pegol-czp-add-on-therapy-to-methotrexate-treatment-in-patients-with-early-rheumatoid-arthritis-was-observed-following-czp-discontinuation-2-year-results-of-the-c-opera-study-a-phase-iii-randomised-trial
#15
Tatsuya Atsumi, Yoshiya Tanaka, Kazuhiko Yamamoto, Tsutomu Takeuchi, Hisashi Yamanaka, Naoki Ishiguro, Katsumi Eguchi, Akira Watanabe, Hideki Origasa, Shinsuke Yasuda, Yuji Yamanishi, Yasuhiko Kita, Tsukasa Matsubara, Masahiro Iwamoto, Toshiharu Shoji, Osamu Togo, Toshiyuki Okada, Désirée van der Heijde, Nobuyuki Miyasaka, Takao Koike
OBJECTIVES: To investigate the clinical impact of 1-year certolizumab pegol (CZP) therapy added to the first year of 2-year methotrexate (MTX) therapy, compared with 2-year therapy with MTX alone. METHODS: MTX-naïve patients with early rheumatoid arthritis (RA) with poor prognostic factors were eligible to enter Certolizumab-Optimal Prevention of joint damage for Early RA (C-OPERA), a multicentre, randomised, controlled study, which consisted of a 52-week double-blind (DB) period and subsequent 52-week post treatment (PT) period...
February 2, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28151971/eq-5d-utility-response-and-drug-survival-in-rheumatoid-arthritis-patients-on-biologic-monotherapy-a-prospective-observational-study-of-patients-registered-in-the-south-swedish-ssatg-registry
#16
Tanja Schjødt Jørgensen, Carl Turesson, Meliha Kapetanovic, Martin Englund, Aleksandra Turkiewicz, Robin Christensen, Henning Bliddal, Pierre Geborek, Lars Erik Kristensen
OBJECTIVES: Biologic agents have dramatically changed treatment of rheumatoid arthritis (RA). To date only scarce head-to-head data exist especially when the biological therapies are given as monotherapy without concomitant disease modifying drugs (DMARDs). Thus the objective of the current study is to evaluate treatment response of all available biological therapies with special focus on utility (EQ-5D-3L) and drug survival of biologic DMARDs (bDMARDs) prescribed as monotherapy in RA patients in southern Sweden...
2017: PloS One
https://www.readbyqxmd.com/read/28150514/maintenance-treatment-using-abatacept-with-dose-reduction-after-achievement-of-low-disease-activity-in-patients-with-rheumatoid-arthritis-matador-a-prospective-multicenter-single-arm-pilot-clinical-trial
#17
Shinsuke Yasuda, Kazumasa Ohmura, Hiroshi Kanazawa, Takashi Kurita, Yujiro Kon, Tomonori Ishii, Yuichiro Fujieda, Satoshi Jodo, Kazuhide Tanimura, Michio Minami, Tomomasa Izumiyama, Takumi Matsumoto, Yoshiharu Amasaki, Yoko Suzuki, Hideki Kasahara, Naofumi Yamauchi, Masaru Kato, Tamotsu Kamishima, Akito Tsutsumi, Hiromitsu Takemori, Takao Koike, Tatsuya Atsumi
OBJECTIVES: To preliminarily evaluate the feasibility of maintenance therapy with reduced dose of intravenous abatacept (ABT) to 250mg/body/month after achieving remission or low disease activity (LDA). PATIENTS AND METHODS: RA patients treated with ABT at 13 sites were enrolled in this prospective interventional pilot study during the period between March 2013 and March 2015. Inclusion criteria were 1) age at 20 years or older, 2) under treatment with intravenous ABT monthly at approved doses, 3) DAS28-CRP lower than 2...
February 2, 2017: Modern Rheumatology
https://www.readbyqxmd.com/read/28144917/impact-of-adalimumab-on-work-productivity-and-activity-impairment-in-japanese-patients-with-rheumatoid-arthritis-large-scale-prospective-single-cohort-anouveau-study
#18
Tsutomu Takeuchi, Ryo Nakajima, Shuichi Komatsu, Kiyotaka Yamazaki, Tomohiro Nakamura, Naoki Agata, Ataru Igarashi, Toshiro Tango, Yoshiya Tanaka
INTRODUCTION: The Adalimumab Non-interventional Trial for Up-verified Effects and Utility (ANOUVEAU) was a large-scale, multicenter, prospective, observational, single-cohort study that evaluated the effects of adalimumab (ADA) on rheumatoid arthritis (RA)-related work productivity and activity impairment (RA-related WPAI) and disease activity in routine rheumatology care in Japan. METHODS: Patients with RA were categorized as paid workers (PWs, ≥35 h/week), part-time workers (PTWs, <35 h/week), or homemakers (HMs, unemployed) and were administered the WPAI for RA (WPAI/RA) questionnaire...
January 31, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28134079/development-and-validation-of-rheumatoid-arthritis-magnetic-resonance-imaging-inflammation-thresholds-associated-with-lack-of-damage-progression
#19
Joshua F Baker, Mikkel Østergaard, Paul Emery, Daniel G Baker, Philip G Conaghan
OBJECTIVES: To determine thresholds for rheumatoid arthritis (RA) magnetic resonance imaging scores (RAMRIS) associated with a low risk of structural damage progression. METHODS: MRI of the dominant hand was performed and RAMRIS scores determined at weeks 0, 24, and 52. X-rays were performed and van der Heijde-Sharp scores (vdHS) determined. In a development cohort (n=297) the changes in MRI erosion score and vdHS score were determined over the 24-week to 52-week interval and progression was defined as change >0...
January 27, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/28132102/comparative-effectiveness-of-treatment-options-after-conventional-dmards-failure-in-rheumatoid-arthritis
#20
Yoon-Kyoung Sung, Soo-Kyung Cho, Dam Kim, Chan-Bum Choi, Soyoung Won, So-Young Bang, Hoon-Suk Cha, Jung-Yoon Choe, Won Tae Chung, Seung-Jae Hong, Jae-Bum Jun, Hyoun Ah Kim, Jinseok Kim, Seong-Kyu Kim, Tae-Hwan Kim, Hye-Soon Lee, Jaejoon Lee, Jisoo Lee, Shin-Seok Lee, Sung Won Lee, Yeon-Ah Lee, Seong-Su Nah, Chang-Hee Suh, Dae-Hyun Yoo, Bo Young Yoon, Sang Cheol Bae
OBJECTIVE: To compare the clinical effectiveness of two treatment strategies for active rheumatoid arthritis (RA) refractory to conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs): starting TNF inhibitors (TNFIs) or changing csDMARDs. METHODS: We used two nationwide Korean RA registries for patient selection. TNFI users were selected from the BIOPSY, which is an inception cohort of RA patients starting biologic DMARDs. As a control group, we selected RA patients with moderate or high disease activity from the KORONA database whose treatment was changed to other csDMARDs...
January 28, 2017: Rheumatology International
keyword
keyword
52663
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"